QIAGEN (QGEN)
(Delayed Data from NYSE)
$46.36 USD
+0.79 (1.73%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $46.38 +0.02 (0.04%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$46.36 USD
+0.79 (1.73%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $46.38 +0.02 (0.04%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
Zacks News
NeoGenomics (NEO) Looks Good: Stock Adds 5.5% in Session
by Zacks Equity Research
NeoGenomics (NEO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Boston Scientific Gets a Boost From MedSurg Arm Amid Coronavirus
by Zacks Equity Research
Within Endoscopy, Boston Scientific (BSX) believes that business recovery started since June.
Passage Bio (PASG) Looks Good: Stock Adds 5.4% in Session
by Zacks Equity Research
Passage Bio (PASG) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Abbott's New Antibody Test Gets FDA's EUA, Test Suite Expands
by Zacks Equity Research
Abbott's (ABT) latest antibody test is expected to give a clearer picture of the rate of recovery post coronavirus infection.
Here's Why You Should Hold on to NuVasive (NUVA) Stock Now
by Zacks Equity Research
Investors are optimistic about NuVasive (NUVA) on continued momentum across several recently-launched products as well as potential in its U.S. Surgical Support business.
Bruker Rides on Nano and MALDI Launches Despite Margin Debacle
by Zacks Equity Research
Bruker (BRKR) has several Bruker NANO products that are being assembled and tested in Malaysia.
Abbott's Data From Interim Clinical Study of ID NOW Positive
by Zacks Equity Research
Abbott's (ABT) recent data from an interim clinical study on its ID NOW COVID-19 rapid test reflects the test's capacity to deliver effective, consistent and reliable performance.
Bio-Rad (BIO) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Bio-Rad (BIO) is optimistic about maintaining robust testing portfolio along with strength in its Life Sciences business.
Evelo Biosciences (EVLO) Looks Good: Stock Adds 5.9% in Session
by Zacks Equity Research
Evelo Biosciences (EVLO) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Five Prime (FPRX) Looks Good: Stock Adds 5.1% in Session
by Zacks Equity Research
Five Prime (FPRX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
NuVasive's (NUVA) MaXcess Retractor Study Results Positive
by Zacks Equity Research
NuVasive's (NUVA) MaXcess retractor's ability to perform lateral surgery in various approaches, including prone position, is validated by favorable study outcome.
Has QIAGEN N.V. (QGEN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (QGEN) Outperforming Other Medical Stocks This Year?
Medtronic Announces U.S. Launch of Adaptix, Expands Portfolio
by Zacks Equity Research
Medtronic (MDT) introduces fully-navigated titanium implant procedure in the United States with the launch of Adaptix Interbody System.
Verastem (VSTM) Jumps: Stock Rises 7.1%
by Zacks Equity Research
Verastem (VSTM) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Walgreens' Pharmacy International Arm Faces Coronavirus Woes
by Zacks Equity Research
Walgreens (WBA) expects the adverse impact of COVID-19 to continue in the fiscal fourth quarter.
Integra (IART) Preliminary Q3 Results Show Recovery in Sales
by Zacks Equity Research
Integra's (IART) sales improvement in the third quarter is broad-based across the major franchises as per preliminary statement.
Here's Why You Should Add NEOGEN (NEOG) to Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about NEOGEN (NEOG) on robust segmental and geographical growth.
FDA Amends Hologic's Aptima's EUA for Asymptomatic Testing
by Zacks Equity Research
The FDA's modified EUA for Hologic's (HOLX) Aptima SARS-CoV-2 assay includes testing of asymptomatic individuals and symptomatic pooling protocol to curb the spread of coronavirus.
Zacks.com featured highlights include: Stamps, QIAGEN, Owens & Minor, Flowers Foods and Lakeland Industries
by Zacks Equity Research
Zacks.com featured highlights include: Stamps, QIAGEN, Owens & Minor, Flowers Foods and Lakeland Industries
Coronavirus Drives Testing Stocks: Is There Room for More Upside?
by Urmimala Biswas
Given the current testing requirements across the world, the diagnostic testing business for COVID-19 is rapidly evolving.
Here's Why You Should Add Globus Medical to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Globus Medical (GMED) on robust product uptake and prominent sales trend improvement since the second quarter.
LabCorp Heat Extraction COVID-19 Test Method Gets FDA's EUA
by Urmimala Biswas
According to LabCorp (LH), this process traps viral particles, eliminating the need for RNA extraction reagents.
Align Technology Rides on Invisalign Amid Coronavirus Woes
by Zacks Equity Research
Align Technology's (ALGN) Invisalign clear aligner has been receiving positive feedback and holds huge long-term market potential.
Teleflex's (TFX) Arrow EZ-IO Gets FDA's Expanded Indications
by Zacks Equity Research
Teleflex's (TFX) recent expanded indications for its IO device provide more time to physicians to establish safe vascular access.
Buy These 5 Low-Beta Stocks to Survive the Choppy Market
by Nilanjan Banerjee
To combat market volatility, create a portfolio of low-beta stocks.